Anesthetics, Neuromuscular Blockers, Reversal Agents & Perioperative Pharmacology

Anesthetic depth in the brain depends exclusively on the partial pressure (tension) of the anesthetic gas in cerebral arterial blood, which equilibrates with alveolar partial pressure (PA / FI ratio). The Blood:Gas Partition Coefficient represents the solubility of an anesthetic in blood relative to alveolar gas. When an agent has a high Blood:Gas Partition Coefficient (such as halothane at 2.54 or isoflurane at 1.40), the blood acts as a massive pharmacologic sink (reservoir): large quantities of gas must dissolve into the bloodstream before arterial partial pressure rises sufficiently to drive gas into the brain, resulting in a slow induction and a slow emergence. Conversely, agents with a very low Blood:Gas Partition Coefficient (such as desflurane at 0.42, nitrous oxide at 0.47, and sevoflurane at 0.65) are poorly soluble in blood; very few molecules dissolve into the blood before the arterial partial pressure rapidly saturates and equilibrates with the brain, producing rapid induction and rapid emergence. Minimum Alveolar Concentration (MAC) is the alveolar concentration at 1 atm that prevents skeletal muscle movement in response to a surgical skin incision in 50% of patients (analogous to ED50 on a quantal dose-response curve). Potency is inversely proportional to MAC (Potency = 1 / MAC): halothane (MAC 0.75%) is highly potent, whereas nitrous oxide (MAC 104%) has low potency and cannot achieve surgical anesthesia alone without causing hypoxia, though coadministering high-volume N2O rapidly concentrates a second volatile agent in the alveoli (the Second Gas Effect) and diffuses into closed air spaces (contraindicated in pneumothorax, bowel obstruction, or middle ear/retinal surgery).

Each inhaled anesthetic exhibits signature organ-system side effects tested on licensing examinations. All volatile halogenated anesthetics (halothane, isoflurane, sevoflurane, desflurane) decrease systemic vascular resistance and mean arterial pressure (except halothane, which reduces cardiac output via direct myocardial depression), increase cerebral blood flow (increasing intracranial pressure in patients with brain tumors or head trauma), cause bronchodilation, and can trigger Malignant Hyperthermia in genetically susceptible patients (note: nitrous oxide does NOT trigger malignant hyperthermia). Halothane is uniquely associated with two major complications: (1) catecholamine sensitization of the myocardium (precipitating fatal ventricular arrhythmias when epinephrine is injected) and (2) Fulminant Halothane Hepatitis—where hepatic CYP2E1 metabolizes halothane into trifluoroacetic acid, which haptenates liver proteins and triggers neoantigen autoantibodies and massive centrilobular hepatic necrosis days after surgery. Sevoflurane has a non-pungent, sweet odor making it the agent of choice for inhalational mask induction in children, though reaction with desiccated carbon dioxide absorbents generates Compound A (a vinyl ether nephrotoxin) and release of inorganic fluoride ions (historically classic for methoxyflurane nephrotoxicity). Desflurane has a pungent, irritating vapor that triggers coughing, laryngospasm, and sympathetic tachycardia during mask induction, so it is used for maintenance rather than inhalation induction.

Propofol (formulated in a milky-white soybean oil, glycerol, and egg lecithin lipid emulsion) potentiates chloride current through the GABA-A receptor complex. It is the preferred agent for routine rapid sequence induction, ambulatory day surgery, and ICU sedation because it possesses potent intrinsic antiemetic activity and rapid, clear-headed emergence. However, propofol causes profound dose-dependent arterial and venous vasodilation and negative inotropy, resulting in marked systemic hypotension (decreasing cerebral perfusion pressure if mean arterial pressure drops precipitously). In pediatric or adult ICU patients receiving high-dose propofol infusions (greater than 4-5 mg/kg/hr for greater than 48 hours), impaired mitochondrial fatty acid beta-oxidation precipitates Propofol Infusion Syndrome (PRIS): refractory high-anion-gap lactic acidosis, severe rhabdomyolysis, hyperkalemia, lipemia, hepatomegaly, and fatal Brugada-like bradyarrhythmias. Etomidate also potentiates GABA-A receptors but is uniquely hemodynamically neutral—producing virtually zero change in heart rate, cardiac output, or systemic vascular resistance—making it the premier induction agent for hypotensive trauma or cardiogenic shock patients. Its two board-tested drawbacks are frequent myoclonic jerks on induction and potent, reversible inhibition of adrenal 11-beta-hydroxylase (CYP11B1), which blocks the conversion of 11-deoxycortisol to cortisol and 11-deoxycorticosterone to corticosterone, precipitating acute adrenal insufficiency in septic shock patients. Thiopental and methohexital (ultra-short-acting barbiturates) decrease cerebral metabolic oxygen consumption (CMRO2) and intracranial pressure, though methohexital uniquely lowers the seizure threshold and is used before electroconvulsive therapy (ECT) to preserve therapeutic seizure duration.

Ketamine, a phencyclidine (PCP) derivative, acts as a noncompetitive antagonist at the central NMDA (N-methyl-D-aspartate) glutamate receptor channel. Unlike GABAergic agents that depress reticular activating system arousal entirely, ketamine uncouples the thalamocortical system from the limbic system, producing 'dissociative anesthesia' in which the patient appears cataleptic with eyes open, nystagmus, and preserved protective airway reflexes while experiencing profound somatic analgesia and amnesia. Centrally, ketamine inhibits neuronal catecholamine reuptake, triggering a sympathetic surge that increases heart rate, cardiac output, and blood pressure, and relaxes bronchial smooth muscle. Thus, ketamine is ideal for hypotensive trauma patients and patients with severe status asthmaticus, whereas it is avoided in patients with uncontrolled hypertension, acute coronary ischemia, aortic dissection, or schizophrenia (due to vivid emergence delirium and hallucinations, which can be blunted with midazolam). Its S-enantiomer, esketamine, is FDA-approved intranasally for treatment-resistant depression with acute suicidal ideation. Dexmedetomidine is a highly selective central alpha-2 adrenergic agonist in the locus coeruleus that produces 'cooperative sedation' (resembling natural non-REM sleep) and analgesia without causing respiratory depression, making it invaluable for ventilator weaning and ICU delirium, with dose-limiting hypotension and bradycardia as its main side effects.

Clinically used local anesthetics are weak bases with pKa values between 7.6 and 9.0. According to the Henderson-Hasselbalch equation for a weak base (pH = pKa + log [Uncharged Base B / Charged Cation BH+]), at normal extracellular physiological pH (7.4), the majority of drug molecules exist in the charged, protonated cationic form (BH+), while a smaller fraction exists in the uncharged, lipophilic free-base form (B). Crucially, ONLY the uncharged lipophilic form (B) can diffuse across the hydrophobic neuronal lipid bilayer into the axoplasm; once inside the slightly more acidic intracellular cytoplasm (pH ~7.0), the molecule re-equilibrates into the charged cationic form (BH+), which is the active species that physically plugs the intracellular pore of the voltage-gated Na+ channel. When a local anesthetic is injected into an infected abscess or inflamed tissue (extracellular pH 5.5 to 6.5), the acidic environment protonates almost 100% of the drug into the charged cationic form (BH+) outside the nerve; trapped extracellularly, it cannot cross the neuronal membrane, resulting in clinical failure of local anesthesia. Across nerve fiber types, small-diameter and myelinated axons with rapid firing rates are blocked first (Type B autonomic preganglionic fibers → Type C unmyelinated pain/temperature → Type A-delta sharp pain → Type A-gamma/beta touch/pressure → large Type A-alpha motor fibers blocked last, recovering in reverse order).

With the solitary exception of cocaine—which intrinsically blocks norepinephrine reuptake (NET) and causes intense local vasoconstriction—all local anesthetics cause local arteriolar vasodilation. Therefore, epinephrine (1:100,000 or 1:200,000) is frequently coadministered with lidocaine or bupivacaine to induce alpha-1 mediated local vasoconstriction, which slows systemic vascular absorption, prolongs the duration of sensory blockade, minimizes surgical site bleeding, and reduces the peak plasma concentration (decreasing systemic toxicity). Epinephrine-containing solutions are traditionally avoided in end-arterial anatomical sites (fingers, toes, penis, tip of nose, earlobes) in patients with severe peripheral vascular disease or Raynaud phenomenon. Two agents—Benzocaine (topical spray used for transesophageal echocardiography) and Prilocaine ( metabolized to ortho-toluidine)—oxidize hemoglobin ferrous iron (Fe2+) to ferric iron (Fe3+), causing acquired Methemoglobinemia (chocolate-brown blood, cyanosis unresponsive to 100% O2, pulse oximetry fixed at 85%; treated with IV Methylene Blue). Accidental intravascular injection of a large dose—especially Bupivacaine, which binds avidly to cardiac Na+ channels during diastole ('slow-in, slow-out' kinetics)—triggers Local Anesthetic Systemic Toxicity (LAST): initial CNS excitation (circumoral numbness, metallic taste, tinnitus, nystagmus, generalized tonic-clonic seizures) progressing rapidly to CNS depression, PR/QRS prolongation, ventricular arrhythmias, and refractory cardiac arrest. Immediate definitive rescue requires airway management, benzodiazepines for seizures, and intravenous 20% Lipid Emulsion (Intralipid), which creates an intravascular 'lipid sink' that extracts lipophilic bupivacaine out of cardiac myocytes.

Succinylcholine consists of two acetylcholine molecules linked together. It acts as a full agonist at the motor endplate nicotinic AChR, producing a persistent depolarization because—unlike native acetylcholine, which is hydrolyzed in milliseconds by synaptic acetylcholinesterase—succinylcholine is resistant to synaptic acetylcholinesterase and must diffuse back into plasma to be hydrolyzed by hepatic/plasma pseudocholinesterase (butyrylcholinesterase). Its rapid onset (45-60 seconds) and brief duration (6-10 minutes) make it a classic agent for rapid sequence intubation (RSI). Succinylcholine paralysis occurs in two distinct phases: during Phase I (Depolarizing) Block, opening of nAChR channels causes disorganized motor unit firing seen clinically as generalized muscle fasciculations, followed immediately by flaccid paralysis because perijunctional voltage-gated Na+ channels become trapped in their inactivated state and cannot reset until the endplate repolarizes. On peripheral nerve stimulation (Train-of-Four, delivering four supramaximal 2-Hz stimuli to the ulnar nerve), Phase I block shows symmetric reduction of all four twitches with NO fade (T4/T1 ratio = 1.0) and no post-tetanic potentiation; administering an acetylcholinesterase inhibitor (neostigmine) during Phase I WORSENS and prolongs paralysis by inhibiting plasma pseudocholinesterase! With prolonged infusion or repeated doses, the receptor undergoes conformational desensitization into a Phase II (Desensitizing) Block, which mimics a non-depolarizing block (exhibiting Train-of-Four fade) and becomes reversible with anticholinesterases. Most importantly, every depolarization opens endplate channels that efflux potassium out of skeletal muscle, raising serum K+ by ~0.5 mEq/L in healthy patients. However, beginning 24 to 48 hours after major thermal burns, crush injuries, denervation (stroke, Guillain-Barre, spinal cord injury, prolonged ICU immobilization), or in Duchenne/Becker muscular dystrophy, skeletal muscle upregulates extrajunctional fetal nicotinic AChRs across the entire sarcolemma; giving succinylcholine causes massive potassium efflux (rising 5-10 mEq/L in minutes) and fatal hyperkalemic cardiac arrest!

Non-depolarizing neuromuscular blockers act as pure competitive antagonists at the alpha-subunits of the motor endplate nicotinic AChR, preventing acetylcholine binding without depolarizing the membrane (therefore causing zero fasciculations). On Train-of-Four (TOF) monitoring, non-depolarizing blockade exhibits progressive fade (T4 disappears first, then T3, T2, and finally T1 as receptor occupancy exceeds 75%-90%) and post-tetanic facilitation. Across anatomical muscle groups, small, rapidly moving muscles are paralyzed first (extraocular muscles → intrinsic muscles of the fingers → neck/pharynx), followed by intercostal muscles, and finally the diaphragm is paralyzed last; recovery occurs in the exact reverse order, meaning the diaphragm recovers first while pharyngeal airway muscles recover last! Among steroidal agents, Rocuronium has the fastest onset (60 seconds at 1.2 mg/kg RSI dosing, making it the safe alternative to succinylcholine in burn/crush/hyperkalemic patients) and is eliminated mainly via hepatobiliary excretion; Vecuronium has intermediate duration with hepatic/renal clearance; Pancuronium is long-acting, renally cleared, and blocks cardiac M2 receptors (causing vagolytic tachycardia). Among benzylisoquinolinium agents, Atracurium and Cisatracurium undergo spontaneous, non-enzymatic Hofmann elimination in plasma (dependent only on normal physiological pH and temperature) and ester hydrolysis, making Cisatracurium the neuromuscular blocker of choice in patients with combined end-stage liver and renal failure (and unlike atracurium, cisatracurium produces negligible laudanosine metabolite and no histamine-induced flushing/bronchospasm).

Neostigmine (and edrophonium/pyridostigmine) is a carbamate reversible acetylcholinesterase inhibitor that blocks enzymatic hydrolysis of acetylcholine at the neuromuscular junction, allowing endogenous acetylcholine to accumulate and competitively displace non-depolarizing blockers from nicotinic receptors. However, because neostigmine increases acetylcholine concentrations indiscriminately at both somatic nicotinic receptors and autonomic muscarinic receptors (causing severe sinus bradycardia, AV nodal block, bronchospasm, bronchorrhea, salivation, and bowel cramping), neostigmine MUST ALWAYS be coadministered with an antimuscarinic agent. Specifically, Glycopyrrolate is paired with neostigmine (and atropine is paired with faster-acting edrophonium) because glycopyrrolate and neostigmine have matched pharmacokinetic onset and duration profiles, and glycopyrrolate is a quaternary ammonium compound that does not cross the blood-brain barrier (preventing postoperative central anticholinergic delirium). Furthermore, neostigmine has a 'ceiling effect': it cannot reverse deep neuromuscular blockade (when zero twitches are present on Train-of-Four) because once 100% of acetylcholinesterase is inhibited, no additional acetylcholine can be generated. Sugammadex solves this limitation: it is a modified gamma-cyclodextrin ring with a lipophilic core that selectively encapsulates steroidal neuromuscular blockers (Rocuronium greater than Vecuronium and much greater than Pancuronium; it has ZERO effect on succinylcholine or benzylisoquinoliniums like cisatracurium). Sugammadex forms an inactive 1:1 guest-host complex in plasma, creating a concentration gradient that rapidly pulls rocuronium off the nicotinic receptor within 2-3 minutes even from profound, zero-twitch blockade, with the complex excreted unchanged in urine. Note: Sugammadex also encapsulates progesterone, rendering hormonal contraceptives ineffective for 7 days (patients must use backup non-hormonal barrier contraception).

Plasma pseudocholinesterase (butyrylcholinesterase, synthesized by the liver) rapidly hydrolyzes succinylcholine, mivacurium, and ester local anesthetics. Approximately 1 in 2,500 individuals is homozygous for an autosomal recessive mutation in the BCHE gene encoding an atypical pseudocholinesterase enzyme that cannot efficiently hydrolyze succinylcholine. Affected patients appear completely healthy preoperatively, but after receiving a standard intubating dose of succinylcholine or mivacurium, they fail to resume spontaneous breathing or movement at the end of a brief surgical procedure, remaining flaccidly paralyzed for 2 to 8 hours. Diagnostic confirmation relies on the Dibucaine Number: dibucaine is an amide local anesthetic that inhibits 80% of normal wild-type pseudocholinesterase activity (Normal Dibucaine Number = 80), inhibits 40%-60% in heterozygotes, and inhibits only 20% of the mutant atypical enzyme in homozygotes (Homozygous Atypical Dibucaine Number = 20). Remember that the Dibucaine Number reflects enzyme quality (genetic structure), NOT enzyme quantity: a patient with severe cirrhosis has low total enzyme activity but a normal Dibucaine Number of 80. Management of unexpected prolonged paralysis from pseudocholinesterase deficiency is strictly supportive: keep the patient sedated (to prevent terrifying awake paralysis) and maintain mechanical ventilation until spontaneous diaphragmatic and Train-of-Four recovery occurs; avoid administering neostigmine during Phase I block, as neostigmine inhibits any residual pseudocholinesterase activity.

Malignant Hyperthermia (MH) is an autosomal dominant pharmacogenetic disorder of skeletal muscle calcium homeostasis caused in greater than 70% of cases by a gain-of-function mutation in the RYR1 gene (encoding the ryanodine receptor type 1 calcium-release channel on the terminal cisternae of the sarcoplasmic reticulum) or less commonly in CACNA1S (dihydropyridine voltage-gated L-type Ca2+ channel on the T-tubule). Exposure to any volatile halogenated inhaled anesthetic (halothane, isoflurane, sevoflurane, desflurane) or the depolarizing blocker succinylcholine causes the mutant RYR1 channel to lock open, flooding the myoplasm with uncontrolled calcium. Sustained sarcoplasmic Ca2+ elevation drives relentless actin-myosin cross-bridge cycling (causing masseter spasm and generalized rigidity) and massive ATP consumption by the SERCA pump, creating an uncoupled hypermetabolic state that consumes oxygen and generates enormous quantities of carbon dioxide, lactic acid, and heat. On board vignettes, the EARLIEST and most sensitive intraoperative sign of Malignant Hyperthermia is an abrupt, unexplained rise in End-Tidal CO2 (ETCO2) on capnography (accompanied by sinus tachycardia and masseter muscle rigidity), whereas high fever (greater than 40°C / 104°F) is a LATE sign! Immediate management requires: (1) discontinuing all volatile anesthetics and succinylcholine immediately and hyperventilating with 100% O2 at high fresh-gas flows; (2) administering intravenous Dantrolene (an RYR1 antagonist that directly binds the ryanodine receptor to block sarcoplasmic reticulum Ca2+ release); and (3) active cooling and treating hyperkalemia/acidosis with IV sodium bicarbonate, insulin/glucose, and calcium (strictly avoiding calcium channel blockers like verapamil/diltiazem, which interact with dantrolene to cause hyperkalemic cardiac arrest).

Neuroleptic Malignant Syndrome (NMS) is an idiosyncratic reaction triggered over days to weeks by dopamine D2 receptor antagonists (typical antipsychotics like haloperidol/fluphenazine, atypical antipsychotics, or antiemetics like metoclopramide/prochlorperazine) or abrupt withdrawal of dopaminergic Parkinson medications (levodopa/carbidopa). Central D2 blockade in the nigrostriatal pathway causes severe generalized 'lead-pipe' muscle rigidity, bradykinesia, and hyporeflexia, while D2 blockade in the anterior hypothalamus impairs heat dissipation, causing high fever, autonomic instability, mutism/encephalopathy, and rhabdomyolysis. Treatment of NMS involves stopping the offending neuroleptic, aggressive IV hydration/cooling, Dantrolene (to relax skeletal muscle directly), and/or a central dopamine agonist (Bromocriptine or Amantadine). In contrast, Serotonin Syndrome evolves rapidly within hours (less than 24 hours) of combining two serotonergic agents (e.g., an SSRI/SNRI/TCA plus an MAOI, linezolid, tramadol, meperidine, dextromethorphan, triptans, MDMA, or St. John's wort). Unlike the sluggish lead-pipe rigidity and hyporeflexia of NMS, Serotonin Syndrome is defined by neuromuscular hyperexcitability: prominent inducible and spontaneous ankle/ocular CLONUS, hyperreflexia (4+ deep tendon reflexes, lower extremities greater than upper extremities), tremor, agitation, mydriasis, and hyperactive bowel sounds/diarrhea. Treatment requires stopping serotonergic agents, benzodiazepines (lorazepam) for agitation/tremor, and the 5-HT2A receptor antagonist Cyproheptadine for refractory cases.